ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

No Link Between Pneumonitis, Taxanes, And Radiation

November 26, 2004

Senate Committee Approves $1.74 Billion for NCI, Seeks Activation of Dietary Intervention Trial

October 19, 1990

Biomed Research Absent from Bush State of the Union.

January 26, 2007

The 99th turned Out Well For Cancer Program, But Several Important Issues Await 100th Congress

October 31, 1986

Cancer Leadership Council Letter Calls For Permanent Leadership of NCI and FDA.

November 22, 2006

Funding Opportunities: Lymphoma Fellowship

June 8, 2001